Scientific and Technical Evaluation of Pharmaceuticals, Inc. [STEPh, Inc.], Announces Availability of New Multiple Sclerosis Competitive Intelligence Service and Demonstration at ACTRIMS/CMSC

RALEIGH, N.C., May 28, 2013 /PRNewswire/ -- STEPh, Inc., a full service medical communications company, announces launch of their Multiple Sclerosis Competitive Intelligence service [MS STEPh Report] (http://www.stephreports.com/).  Dr. Jay H. Bauman, President of STEPh, Inc., will be in Orlando at ACTRIMS/CMSC to provide a demonstration of this innovative investigational drug information service and to review subscription options.   

About STEPh Reports

STEPh Reports are comprehensive, regularly updated, fully referenced, critical reviews of investigational drugs in preclinical development through NDA approval. 

STEPh Reports are available for Corporate and individual purchase by yearly subscription to the web site.  Subscriptions can also be purchased at a nominal charge through a sponsorship category.  

About MS STEPh Report

The MS STEPh Report is a 300 page review, including more than 20 tables, of nearly 70 compounds and development programs.  Categories of agents that have drawn most research interest include oral compounds, S1P modulators, mAbs, and improved/longer-acting versions of interferon.  Vaccines and stem cell therapies are also under study. 

The MS STEPh Report assesses the competitive landscape by drug monograph, MOA, clinical data, projected launch year, company, and key issues. 

MS STEPh Report Table of Contents

• Oral Agents

• mAbs

• S1P Agonists

• Vaccines, Interferons

• Agents Part of Combination or vs. Active Comparator

• Agents for CIS, PPMS, and SPMS

• Agents for NMO

• Licensing Candidates

• Companies Involved in MS Research

• Individual Drug Monographs

Complementary Features to MS STEPh Report

Additional features include daily and archival news services, manipulative pipeline tables, mini reviews of Hot Topics (e.g., PML and Tysabri, Management of Progressive forms of MS, Novel Interferons), and links to key resources.  STEPh, Inc., attends scientific meetings and provides coverage of key issues at ACTRIMS, ECTRIMS, and AAN.  A Q&A service is also available. 

Meet Dr. Jay Bauman at ACTRIMS/CMSC

Dr. Bauman will be at the ACTRIMS/CMSC meeting in Orlando and is available to meet with individuals interested in learning more about MS STEPh Report or other offered services (medical writing, medical information).  Contact Dr. Bauman by phone or e-mail listed below.

About STEPh, Inc.

STEPh, Inc., was formed in 2005 by pharmaceutical industry veterans.  Dr. Bauman is accomplished author, former Editor of Hospital Edition of US Pharmacist, and founding member of Medical Communications subgroup of DIA. 

Contact
Dr. Jay Bauman
President, STEPh, Inc.
919-818-4942 (cell)
http://www.stephreports.com/
[email protected]

SOURCE Scientific and Technical Evaluation of Pharmaceuticals, Inc.